Employees  Clients  Members  Annual Adjusted Prescriptions  Generic Dispensing Ratio  2017 Revenue  27,000  3,000  ~80 million  1.4 billion  86.2%  $100.1 billion  Express Scripts: Premier Pharmacy Management Platform  Express Scripts keeps patients at the center of everything it does  CIGNA & EXPRESS SCRIPTS:KEY FACTS ON EXPRESS SCRIPTS   JOINING FORCES WITH A DIVERSE, HIGH-PERFORMING PHARMACY PORTFOLIOTO MAKE PRESCRIPTION DRUGS SAFER AND MORE AFFORDABLE FOR MILLIONS OF AMERICANS  Express Scripts Fact Sheet  30+ years of innovation and cost containment for clientsFocus on simultaneously improving affordability and clinical outcomesPuts medicine within reach of 83+ million peopleTechnology-focused solutions utilizing specialized care models and 1.4 billion patient interactions annually Provides tools to align and engage patients, physicians and employers                                                                                  Innovative Solutions to Improve Care, Cost and Value  How Express Scripts is Paid for the Value it Delivers  Sells its programs and services as an integrated offering, selling various "baskets" of programs and services and prices accordinglyHelps identify the medications that create the most positive health outcomes, enabling customers to get the right medication, in the right dosage, at the right time (for the appropriate duration), at a fair price. In addition, unlocks greater value, and reduce costs, by providing customers with information about options of where to access to care – dispensing for economic valueProvides a number of funding arrangements for clients – including fee based payments, full pass through of rebates, rebate sharing and value-based pricingPricing arrangements align interests – Express Scripts is generally only successful when its clients save money    Client  Express Scripts  ServicesProgramsPurchase DiscountsRebatesGuarantees  Needs  Solutions  Various Pricing Packages  Transparency and comprehensive solutions align customer value with financial performance  1  2  3  4  Supply chain / Formulary managementEncourages use of generics and preferred brandsNegotiates discounts from drug manufacturers Claims processingHas auto-adjudication capabilities that process claims instantlyPromotes patient safety through prospective drug utilization reviews to avoid adverse drug to drug interactionsMail order pharmacy330+ million adjusted prescriptions dispensed annuallyRetail pharmacy network managementCreates preferred network of aligned retail pharmacies Specialty pharmacyManages high-cost specialty medications  Pharmacy Management Capabilities  Employs 3,000+ health care professionals to close gaps in care (e.g., improve adherence and reduce waste)Helps those who struggle with complex diseases (e.g., cancer, HIV, mental illness) that require a special focus and care model Specialty pharmacy, Accredo®, helps bring together a customer’s pharmacy, medical and home-based services to drive better outcomesLaunched two new SafeGuardRx programs in 2017 (in addition to 7 existing programs) to improve care by targeting therapy classes that pose clinical challenges for customers and a significant budget threat to their clients (e.g., inflammatory conditions, diabetes)Acquired eviCore, an innovative evidence-based medical benefit management services company that provides utilization management services for health plans and employers and more  Clinical Capabilities  Achieved 1.5% pharmacy trend in 2017 – lowest in its history44% of clients spent less per person on prescription drugs in 2017 than in 2016 – a negative drug trendVast majority of customers saw out-of-pocket costs hold steady at about 14% of total prescription drug cost; the average customer copay increased by just 12 centsExpress Scripts’ clinical programs returned $32 billion in savings to its clients in 2017  Purchase Discounts and Rebates  Today: On average, Express Scripts passes through ~90% of the rebates it receives. If clients prefer full pass through, Express Scripts facilitates and adjusts pricing for the basket of services and programsWhat would happen if rebates went away: Express Scripts would continue to negotiate lower prices from pharmacies and pharmaceutical manufacturers and pass through those savings to its clients. Clients would use an alternate funding / pricing structure     

 FORWARD LOOKING STATEMENTSInformation included or incorporated by reference in thiscommunication, and information which may be contained inother filings with the Securities and Exchange Commission(the “SEC”) and press releases or other public statements,contains or may contain forward-looking statements. Theseforward-looking statements include, among other things,statements of plans, objectives, expectations (financial orotherwise) or intentions.Forward-looking statements, including as they relate to ExpressScripts (“Express Scripts”) or Cigna (“Cigna”), the managementof either such company or the transaction, involve risks anduncertainties. Actual results may differ significantly from thoseprojected or suggested in any forward-looking statements.Express Scripts and Cigna do not undertake any obligationto release publicly any revisions to such forward-lookingstatements to reflect events or circumstances occurring afterthe date hereof or to reflect the occurrence of unanticipatedevents. Any number of factors could cause actual results todiffer materially from those contemplated by any forward looking statements, including, but not limited to, the risksassociated with the following:the inability of Express Scripts and Cigna to obtain stockholder or regulatory approvals required for the merger or the requirement to accept conditions that could reduce the anticipated benefits of the merger as a condition to obtaining regulatory approvals;a longer time than anticipated to consummate the proposed merger;problems regarding the successful integration of the businesses of Express Scripts and Cigna;unexpected costs regarding the proposed merger;diversion of management’s attention from ongoing businessoperations and opportunities;potential litigation associated with the proposed merger;the ability to retain key personnel;the availability of financing;effects on the businesses as a result of uncertainty surrounding the proposed merger; andthe industry may be subject to future risks that are described in SEC reports filed by Express Scripts and Cigna.You should carefully consider these and other relevant factors,including those risk factors in this communication and otherrisks and uncertainties that affect the businesses of ExpressScripts and Cigna described in their respective filings with theSEC, when reviewing any forward-looking statement. Thesefactors are noted for investors as permitted under the PrivateSecurities Litigation Reform Act of 1995. Investors shouldunderstand it is impossible to predict or identify all such factorsor risks. As such, you should not consider either foregoing lists,or the risks identified in SEC filings, to be a complete discussionof all potential risks or uncertainties.IMPORTANT INFORMATION ABOUT THE TRANSACTIONAND WHERE TO FIND ITThis communication does not constitute an offer to buy orsolicitation of an offer to sell any securities. In connectionwith the proposed transaction, the newly formed companywhich will become the holding company following thetransaction (“Holdco”) intends to file with the SEC a registrationstatement on Form S-4 that will include a joint proxy statementof Cigna and Express Scripts that also constitutes a prospectusof Holdco. Cigna and Express Scripts also plan to file other relevant documents with the SEC regarding the proposedtransaction.   INVESTORS AND SECURITY HOLDERS AREURGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. You may obtain a free copy of the joint proxy statement/prospectus (if and when it becomes available) and other relevant documents filed by Holdco, Cigna and Express Scripts with the SEC at the SEC’s website at www.sec.gov. Copies of documents filed with the SEC by Cigna will be available free of charge on Cigna’s website at www.Cigna.com or by contacting Cigna’s Investor Relations Department at (215) 761-4198. Copies of documents filed with the SEC by Express Scripts will be available free of charge on Express Scripts’ website at www.express-scripts.com or by contacting Express Scripts’ Investor Relations Department at (314) 810-3115.PARTICIPANTS IN THE SOLICITATIONCigna (and, in some instances, Holdco) and Express Scriptsand their respective directors and executive officers may bedeemed to be participants in the solicitation of proxies inrespect of the proposed transaction under the rules of theSEC. Investors may obtain information regarding the names,affiliations and interests of directors and executive officers ofCigna (and, in some instances, Holdco) in Cigna’s Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on February 28, 2018, and its definitive proxy statement for its 2018 Annual Meeting, which was filed with the SEC on March 16, 2018. Investors may obtain information regarding the names, affiliations and interests of Express Scripts’ directors and executive officers in Express Scripts’ Annual Report on Form 10-K for the year ended December 31, 2017, which was filed with the SEC on February 27, 2018, and its proxy statement for its 2018 Annual Meeting, which was filed with the SEC on March 29, 2018. You may obtain free copies of these documents at the SEC’s website at www.sec.gov, at Cigna’s website at www.Cigna.com or by contacting Cigna’s Investor Relations Department at (215) 761-4198. Copies of documents filed with the SEC by Express Scripts will be available free of charge on Express Scripts’ website at www.express-scripts.com or by contacting Express Scripts’ Investor Relations Department at (314) 810-3115. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction if and when they become available. Investors should read the joint proxy statement/prospectus carefully and in its entirety when it becomes available before making any voting or investment decisions.NO OFFER OR SOLICITATIONThis communication is for informational purposes only and notintended to and does not constitute an offer to subscribe for,buy or sell, the solicitation of an offer to subscribe for, buy orsell or an invitation to subscribe for, buy or sell any securitiesor the solicitation of any vote or approval in any jurisdictionpursuant to or in connection with the proposed transactionor otherwise, nor shall there be any sale, issuance or transferof securities in any jurisdiction in contravention of applicablelaw. No offer of securities shall be made except by means ofa prospectus meeting the requirements of Section 10 of theSecurities Act of 1933, as amended, and otherwise in accordance with applicable law.